Quantcast
Channel: WN.com - Articles related to Preclinical Data of Xencor's XmAb Bispecific Technology to be Presented at Upcoming ASH Annual Meeting
Browsing all 614 articles
Browse latest View live

Xencor to Host Third Quarter 2016 Financial Results Webcast and Conference...

(Source: Xencor Inc) MONROVIA, Calif., Oct. 26, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...

View Article


Xencor to Present at Upcoming Investor Conferences (Xencor Inc)

(Source: Xencor Inc) MONROVIA, Calif., Oct. 31, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...

View Article


Preliminary Data from the Ongoing Open-Label XmAb5871 Phase 2 Pilot Study in...

(Source: Xencor Inc) MONROVIA, Calif., Oct. 3, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...

View Article

Xencor Initiates Phase 1b Trial of Subcutaneous Formulation of XmAb7195...

(Source: Xencor Inc) MONROVIA, Calif., Sept. 15, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...

View Article

Xencor Appoints A. Bruce Montgomery, M.D. to Board of Directors (Xencor Inc)

(Source: Xencor Inc) MONROVIA, Calif., March 19, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...

View Article


Xencor Appoints Yujiro S. Hata to Board of Directors

MONROVIA, Calif., July 31, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

View Article

Xencor Reports Complete Data Results on XmAb5871 Program at European League...

MONROVIA, Calif., June 10, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

View Article

Xencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and...

MONROVIA, Calif., March 7, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

View Article


Xencor Appoints Yujiro S. Hata to Board of Directors (Xencor Inc)

(Source: Xencor Inc) MONROVIA, Calif., July 31, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...

View Article


Xencor Reports Complete Data Results on XmAb5871 Program at European League...

(Source: Xencor Inc) MONROVIA, Calif., June 10, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...

View Article

Xencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and...

(Source: Xencor Inc) MONROVIA, Calif., March 7, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...

View Article

Xencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory...

MONROVIA, Calif., May 13, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

View Article

Xencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory...

(Source: Xencor Inc) MONROVIA, Calif., May 13, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...

View Article


Xencor Reports Second Quarter 2014 Financial Results Conference call today at...

, July 31, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and...

View Article

Xencor Reports Second Quarter 2014 Financial Results (Xencor Inc)

(Source: Xencor Inc) Conference call today at 4:30 p.m. EDT MONROVIA, Calif., July 31, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered...

View Article


Xencor Reports Third Quarter 2014 Financial Results Conference call today at...

, Nov. 10, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and...

View Article

Xencor Reports Third Quarter 2014 Financial Results (Xencor Inc)

(Source: Xencor Inc) Conference call today at 4:30 p.m. EST MONROVIA, Calif., Nov. 10, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered...

View Article


Xencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and...

(Source: Xencor Inc) Focusing development on rare autoimmune disorder IgG4-related disease (IgG4-RD) Ongoing Phase 1b/2a clinical trial on track to report topline results by end of 2014 Conference call...

View Article

Xencor to Host R&D Day and Webcast on June 26, 2015

MONROVIA, Calif., June 12, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

View Article

Xencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and...

MONROVIA, Calif., Oct. 28, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

View Article
Browsing all 614 articles
Browse latest View live


<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>